Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting

Highly selective oral SMARCA2 degrader, PRT7732, shows robust anti-tumor activity in vivo as monotherapy and in combination with chemotherapy, at well-tolerated doses Potentially best-in-class CDK9...

Related Keywords

United States ,American ,Andrew Combs ,Peggy Scherle ,Helen Shik ,Lindsey Trickett ,Exchange Commission ,Linkedin ,American Association For Cancer Research ,Shik Communications ,Prelude Therapeutics Incorporated Nasdaq ,Therapeutics Incorporated ,American Association ,Cancer Research ,Annual Meeting ,Chief Chemistry Officer ,Chief Scientific Officer ,Preclinical Characterization ,Highly Potent ,Orally Bioavailable Targeted Protein Degrader ,Novel Highly Selective Cyclin Dependent Kinase ,Has Potent Antitumor Activity ,Various Lymphoid ,Brain Penetrant ,Highly Effective ,Preclinical Models ,Breast Cancer ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Markets ,